Study | Garufi | Sougklakos | ASSENAT | Saridaki | Folprecht | Fornaro | Bendell | Pietrantonio | Cremolini | Modest | Ogata | Samalin | Deng | Tsuji |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Methodological items for non-randomized studies | ||||||||||||||
 A clearly stated aim | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
 Inclusion of consecutive patients | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
 Prospective collection of data | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 |
 Endpoints appropriate to the aim of study | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
 Unbiased assessment of the study endpoint | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
 Follow-up period appropriate to the aim of the study | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
 Loss to follow up less than 5% | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
 Prospective calculation of the study size | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 0 |
Additional criteria for comparative studies | ||||||||||||||
 An adequate control group | - | - | - | - | 2 | - | - | - | 2 | - | 2 | - | - | 2 |
 Contemporary groups | - | - | - | - | 2 | - | - | - | 2 | - | 2 | - | - | 2 |
 Baseline equivalence of groups | - | - | - | - | 2 | - | - | - | 2 | - | 2 | - | - | 2 |
 Adequate statistical analyses | - | - | - | - | 2 | - | - | - | 2 | - | 2 | - | - | 2 |
 Total | 16 | 14 | 16 | 16 | 22 | 16 | 16 | 14 | 24 | 14 | 21 | 13 | 16 | 22 |